2006
DOI: 10.1002/humu.9422
|View full text |Cite
|
Sign up to set email alerts
|

The Cypriot and Iranian National Mutation Frequency Databases

Abstract: The National Mutation Frequency Databases are continuously updated mutation depositories, which contain extensive information over the described genetic heterogeneity of an ethnic group or population. Here, we report the construction of the Cypriot (http://www.goldenhelix.org/cypriot) and Iranian National Mutation Frequency Databases (http://www.goldenhelix.org/iranian), both derived from an academic effort to provide high quality and up-to-date information on the underlying genetic heterogeneity of inherited … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0
1

Year Published

2006
2006
2018
2018

Publication Types

Select...
6
1

Relationship

4
3

Authors

Journals

citations
Cited by 21 publications
(12 citation statements)
references
References 32 publications
0
11
0
1
Order By: Relevance
“…These resources have recently emerged, mostly driven by the need to document the varying mutation spectrum observed for any gene (or multiple genes) associated with a genetic disorder, among different population and ethnic groups [10]. The first NEMDBs to come online were the Finnish database (http: //www.findis.org) [21], and the various NEMDBs that are available at the Golden Helix Server (http: //www.goldenhelix.org) [22,23]. In the latter case, a specialized database management system was introduced, namely ETHNOS (available in both flat-file and relational database format) that enables both basic query formulation and restrictedaccess data entry so that all records are manually curated to ensure high and consistent data quality [24].…”
Section: Expanding the Nemdbs Concept Into Pharma-cogenomicsmentioning
confidence: 99%
“…These resources have recently emerged, mostly driven by the need to document the varying mutation spectrum observed for any gene (or multiple genes) associated with a genetic disorder, among different population and ethnic groups [10]. The first NEMDBs to come online were the Finnish database (http: //www.findis.org) [21], and the various NEMDBs that are available at the Golden Helix Server (http: //www.goldenhelix.org) [22,23]. In the latter case, a specialized database management system was introduced, namely ETHNOS (available in both flat-file and relational database format) that enables both basic query formulation and restrictedaccess data entry so that all records are manually curated to ensure high and consistent data quality [24].…”
Section: Expanding the Nemdbs Concept Into Pharma-cogenomicsmentioning
confidence: 99%
“…Major disadvantages are the many incomplete fields for various disorders and/or genes (partly justified from the project's short lifespan) and the lack of mutation frequency information. The ETHNOS-based NEMDBs, namely the Hellenic [Patrinos et al, 2005b], Cypriot, Iranian [Kleanthous et al, 2006], Lebanese [Megarbane et al, 2006], and Serbian National Mutation Frequency Databases, report the frequencies of mutant alleles responsible for several inherited disorders in those populations. In addition to compiled information on each disorder (the gene involved, diagnosis, and treatment), mutation frequency data are provided, accompanied by links to OMIM and LSDBs where possible (Supplementary Figure S1).…”
Section: General Impression and Comparison Between The Existing Nemdbsmentioning
confidence: 99%
“…Also, the GHI developed ETHNOS, an off-the-shelf bioinformatics suite to facilitate development and curation of National/Ethnic Genetic and Mutation frequency databases [3]. This software has enabled the development of a number of these resources in various populations, such as Greek [4], Cypriot, Iranian [5], Lebanese, Israeli [6], and Egyptian. Also, based on the same concept, FINDbase [103], a worldwide database to record frequencies of causative mutations and pharmacogenetic markers, has been developed [7].…”
Section: European-wide Application Of Pharmacogenomicsmentioning
confidence: 99%